

STREPTOCOCCUS PNEUMONIAE PROTEINS AND VACCINES

5

This application is a Divisional of Serial No. 09/590,991, filed 9 February 2000, which claims priority of U.S. provisional application 60/138,453, filed June 10, 1999, the disclosure of which is hereby incorporated by reference in its entirety.

10

BACKGROUND OF THE INVENTION

Streptococcus pneumoniae is a gram positive bacterium which is a major causative agent in invasive infections in animals and humans, such as sepsis, meningitis, otitis media and lobar pneumonia (Tuomanen, et al. NEJM 322:1280-1284 (1995)). As part of the infective process, pneumococci readily bind to non-inflamed human epithelial cells of the upper and lower respiratory tract by binding to eukaryotic carbohydrates in a lectin-like manner (Cundell et al., Micro. Path. 17:361-374 (1994)). Conversion to invasive pneumococcal infections from bound bacteria may involve the local generation of inflammatory factors which may activate the epithelial cells to change the number and type of receptors on their surface (Cundell, et al., Nature, 377:435-438 (1995)). Apparently, one such receptor, platelet activating factor (PAF) is engaged by the pneumococcal bacteria and within a very short period of time (minutes) from the appearance of PAF, pneumococci exhibit strongly enhanced adherence and invasion of tissue. Certain soluble receptor analogs have been shown to prevent the progression of pneumococcal infections (Idanpaan-Heikkila et al., J. Inf. Dis., 176:704-712 (1997)). A number of various other proteins have been suggested as being involved in the pathogenicity of *S. pneumoniae* but only some have been

confirmed as virulence factors. Despite the fact that there are capsule conjugates currently in trial, there still remains a need for identifying additional polypeptides having epitopes in common from various strains of *S. pneumoniae* in order to utilize such polypeptides as vaccines to provide protection against a wide variety of *S. pneumoniae* serotypes.

10

BRIEF SUMMARY OF THE INVENTION

15

The invention disclosed herein relates to vaccines derived from polypeptides of the pneumococcal organism *Streptococcus pneumoniae*. In accordance with the present invention there are disclosed herein several protein sequences, and fragments thereof and their corresponding nucleotide sequences used for recombinantly preparing said polypeptides.

20

More specifically, the present invention discloses 2 large polypeptides, one denoted Sp128 (SEQ ID NO:6), composed of 664 amino acid residues, and a second polypeptide, denoted Sp130, containing 773 amino acid residues (SEQ ID NO:8). Both Sp128 and Sp130 have been found to confer protective properties on animals immunized with said polypeptides, or portions thereof.

25

The present invention also relates to the field of bacterial antigens and their use, for example, as immunogenic agents in humans and animals to stimulate an immune response. More specifically, it relates to the vaccination of mammalian species with one or more recombinant polypeptides produced according to the invention disclosed herein, such recombinant polypeptides being derived from *Streptococcus pneumoniae*.

30

In accordance with the present invention, such proteins serve as a mechanism

for stimulating production of antibodies that protect the vaccine recipient against infection by a wide range of capsular serotypes of pathogenic *S. pneumoniae*.

The invention disclosed herein further relates to antisera and antibodies against such polypeptides useful in diagnosis and passive immune therapy with respect to diagnosing and treating such pneumococcal infections. Like the vaccines disclosed herein, the antibodies specific for such antigenic polypeptides, and fragments thereof, can be prepared recombinantly by transforming cells with vectors containing the appropriate gene sequences to produce the active tetrameric antibody. Such methods are well known in the art.

In a particular aspect, the present invention relates to the prevention and treatment of pneumococcal infections such as infections of the middle ear, nasopharynx, lung and bronchial areas, blood, CSF, and the like, that are caused by pneumococcal bacteria.

The present invention further relates to vaccines prepared from the novel proteins and polypeptides, as well as fragments and segments thereof, disclosed herein. In addition, examples of the use of such proteins and polypeptides as vaccines for the protection of mammals are likewise disclosed.

BRIEF DESCRIPTION OF THE DRAWINGS

25

Figure 1 shows the results of 2 experiments (Figs 1A and 1B, respectively), using the same preparations of Sp128 and Sp130 polypeptides. The results demonstrate that active immunization with recombinant Sp128 or Sp130 polypeptides derived from the pneumococcal strain Norway serotype 4 is able to protect mice from death in a model of pneumococcal sepsis using the

heterologous strain SJ2 (serotype 6B). In these 2 experiments, 90% and 100%, respectively, of the mice immunized with Sp130 survived the 14 day observation period following challenge with about 400 CFU (colony forming units) of pneumococci. Conversely, 100% of sham immunized mice (injected only with PBS (phosphate-buffered saline) plus adjuvant) died during the same period. In addition, for both experiments, 90% of the mice immunized with Sp128 survived the same 14 day observation period.

Figure 2 shows the results of passive administration of rabbit antiserum raised against Sp130 derived from Norway serotype 4. Such administration was able to protect mice in the pneumococcal sepsis model using a heterologous strain. More specifically, 70% of the mice immunized with the Sp130 antiserum survived the 10 day observation period after challenge with 1400 CFU of strain WU2 (serotype 3). In addition, 100% of the mice immunized with a control serum (collected before immunization) died by day 4.

Figure 3 is a western blot showing reactivity of antisera raised against recombinant Sp130 (derived from strain Norway serotype 4) with whole cell lysates of heterologous strains. All *S. pneumoniae* strains tested showed a band of molecular weight about 220 kD, the expected mass for a protein containing both the Sp128 and Sp130 sequences, indicating that this protein was present in all of the tested strains. Tested strains included isolates from each of the pneumococcal serotypes represented in the currently used 23-valent polysaccharide vaccine.

Figure 4 is a western blot showing the reactivity of patient sera with either Sp128 or Sp130. Fig. 4A shows the results for Sp128. Fig. 4B shows the results for Sp130. The recombinant proteins were resolved by SDS-PAGE and transferred to nitrocellulose. Sera were collected from 5 patients (indicated by number at the top) at two different times. First collection (denoted "A" for "acute serum") was soon after onset of illness; second collection (denoted "C" for "convalescent") was made 8 to 30 days later. These sera were used to probe the blots. The results

show that for patients 2, 3 and 5, convalescent serum reacted more strongly with Sp128 and Sp130 than did the corresponding acute serum. Such findings constitute indirect evidence that both Sp128 and Sp130 are expressed by *S. pneumoniae* during this phase of infection.

5

DETAILED SUMMARY OF THE INVENTION

10

In accordance with the present invention there is disclosed herein recombinant polypeptides corresponding to Sp128 (SEQ ID NO: 6) and Sp130 (SEQ ID NO: 8).

15

It is an object of the present invention to provide methods of utilizing these recombinant polypeptides, and immunogenically active fragments thereof, as a means of immunizing animals, especially mammals, most especially humans, against a variety of microbial infections, especially pneumococcal infections.

20

It is a further object of the present invention to provide polypeptides, as disclosed herein, and active fragments thereof, whether derived from natural sources or prepared by means of recombinant technology, for use in immunizing animals, especially mammals, most especially humans, against pneumococcal infection.

25

It is a still further object of the present invention to provide vaccines that include polypeptides obtained from *S. pneumoniae* and/or variants of said polypeptides and/or active fragments of such polypeptides, including polypeptides prepared by recombinant means (i.e., recombinant polypeptides and proteins).

30

In accordance with the present invention, there are also disclosed herein nucleic acids and DNA sequences and molecules, and fragments thereof (and their corresponding isolated RNA sequences, and molecules and fragments thereof) showing sequence homology with, or identity to, or capable of hybridizing to, the DNA sequences identified in SEQ ID NOS: 5 and 7. The present invention also relates to DNA (or RNA) sequences encoding the same polypeptide as is encoded by the sequences of SEQ ID NOS: 5 and 7, including fragments and portions thereof and, when derived from natural sources, including alleles thereof, for the express purpose of facilitating the recombinant expression of the immunogenic polypeptides, and immunogenic fragments thereof, disclosed herein.

Thus, an isolated DNA (or RNA) sequence can include only the coding region of the expressed gene (or fragment or portion thereof as hereinabove indicated) or can further include all or a portion of the non-coding DNA (or RNA) of the expressed human gene.

In accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$25 \quad \text{Percent Identity} = 100 [1-(C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or

amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

In accordance with the present invention, there are disclosed herein the polynucleotide sequences coding for the polypeptide vaccines of the invention so as to facilitate recombinant expression of said polypeptides. Such polynucleotides code for the polypeptides of SEQ ID NOS: 6 and 8 and are disclosed as the sequences of SEQ ID NOS: 5 and 7.

For purposes of recombinantly expressing the polypeptide vaccines of the invention, the polynucleotides of SEQ ID NOS: 5 and 7 may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptide of the present invention. The marker sequence may be a hexahistidine tag (for example, as can be supplied by a pQE-9 vector) to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).

To facilitate generation of the polynucleotides disclosed herein, appropriate PCR primers are provided as SEQ ID NOS: 1 (5'-primer for Sp128), 2 (3'-primer for Sp128), 3 (5'-primer for Sp130), and 4 (3'-primer for Sp130).

5

The polypeptides, and fragments thereof, of the vaccines disclosed as expression products according to the invention may be in "enriched form." As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

10

"Isolated" in the context of the present invention with respect to polypeptides means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such polypeptides could be part of a composition, and still be isolated in that such composition is not part of its natural environment. The polypeptides of the vaccines disclosed herein are preferably provided in an isolated form, and preferably are purified to homogeneity.

15

The recombinant or immunogenic polypeptides disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been

conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, claimed polypeptide which has a purity of preferably 5 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.

The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural 10 genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

15 The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

20 At the simplest level, the amino acid sequence corresponding to all or part of the polypeptides according to the present invention can be synthesized using commercially available peptide synthesizers. This is particularly useful in producing small peptides and fragments of larger polypeptides. (Fragments are useful, for example, in generating antibodies against the native polypeptide.)

25 The terms "fragment," "derivative" and "analog," when referring to the polypeptides according to the present invention, means a polypeptide which retains essentially the same biological function or activity as said polypeptide. Thus, an analog includes a proprotein which can be activated by cleavage of the 30 proprotein portion to produce an active mature polypeptide. Such fragments, derivatives and analogs must have sufficient similarity to the polypeptides SEQ ID

NOS: 6 and 8, so that activity of the native polypeptide is retained.

The polypeptide vaccines of the present invention may be recombinant polypeptides, natural polypeptides or synthetic polypeptides, preferably recombinant polypeptides.

"Recombinant," as used herein, means that a protein is derived from recombinant (e.g., microbial or mammalian) expression systems. "Microbial" refers to recombinant proteins made in bacterial or fungal (e.g., yeast)

expression systems. As a product, "recombinant microbial" defines a protein essentially free of native endogenous substances and unaccompanied by associated native glycosylation. Protein expressed in most bacterial cultures, e.g., E. coli, will be free of glycosylation modifications that might normally occur in yeast or mammalian expression systems. Thus, the patterns of such post-translational modifications will differ with the expression system. However, all such variants are considered to lie within the disclosure of the present invention.

A vaccine according to the present invention would include a polypeptide, including immunogenic fragments thereof, comprising an amino acid sequence at least 65% identical, preferably 80% identical, most preferably 95% identical and ideally 100% identical to the amino acid sequence of SEQ ID NO:6.

Such vaccines would also comprise a polypeptide, including immunogenic fragments thereof, having an amino acid sequence at least 65% identical, preferably 80% identical, most preferably 95% identical, and ideally 100% identical to the amino acid sequence of SEQ ID NO:8.

The present invention is also directed to an antiserum produced by immunizing an animal with a polypeptide according to the invention. The invention also includes and isolated antibody that binds specifically to a polypeptide of the invention. Such an antibody may be a monoclonal antibody,

possibly produced by a hybridoma cell line, and may also include a recombinantly produced antibody formed by introducing into a suitable cell line the gene sequences required for producing an antibody specific for the polypeptide vaccines disclosed herein.

5

The present invention is also directed to a vaccine comprising one or more *S. pneumoniae* polypeptides selected from the polypeptides, and immunogenic fragments thereof, disclosed herein, suspended in a pharmaceutically acceptable diluent, carrier or excipient, provided that said polypeptide is present in an amount effective to elicit protective antibodies in an animal against an organism related to the genus *Streptococcus*, preferably an organism of the genus *Streptococcus*, and most preferably where the organism is *Streptococcus pneumoniae*.

15 The present invention also provides for a method of preventing or treating an infection caused by a member of the genus *Streptococcus* in an animal, comprising administering to an animal, especially a mammal, and most especially a human being, a polypeptide, or immunogenic fragment thereof, as disclosed herein, and wherein said polypeptide, or immunogenic fragment thereof, is administered in an amount effective to prevent or attenuate said infection. In using the methods of the invention, the disease to be prevented or treated will preferably be a pneumococcal infection, most preferably an infection by an organism that is a member of the genus *Streptococcus*, ideally *Streptococcus pneumoniae*.

25

A vaccine disclosed according to the present invention may also include a vaccine comprising a microbial organism transformed with polynucleotides, and thereby expressing the polypeptides, or fragments thereof, selected from the group consisting of Sp128 and Sp130 (SEQ ID NOS: 6 and 8, respectively). The present invention would thus also encompass a method of preventing or attenuating an infection caused by a member of the genus *Streptococcus* in an

animal, especially a mammal, most especially a human, comprising administering to said animal such a vaccine, wherein said vaccine is administered in an amount effective to prevent or attenuate said infection. In applying the method of the invention, the transformed microorganism is selected
5 from the group consisting of *Salmonella*, *Mycobacteria*, *Streptococcus*, poxviruses, and adenoviruses.

Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for
10 producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

The immunogenic fragments of the polypeptide vaccines disclosed according to the invention will include immunogenic fragments of Sp128 (SEQ ID NO:6), which fragments can be readily screened for immunogenic activity, as well as immunogenic fragments of Sp130 (SEQ ID NO:8). For example, in the amino acid sequence of Sp130, the fragment corresponding to residues 657 through 773 are known to provide about 40% protection versus the entire Sp130 sequence. Thus, the former fragment protects about 4 out of 10 mice challenged with *Streptococcus pneumoniae* versus 10 of 10 for the entire Sp130 sequence. Thus, specific fragment may include the fragments having amino acid sequences 650 – 773, 640 – 773, 630 – 773, 620 – 773, 610 – 773, 600 – 773, and similar fragments up to the entire Sp130 sequence (SEQ ID NO: 8). It is logical to presume that fragments of Sp128 (SEQ ID NO: 6) may provide similar degrees of protection versus the entire Sp128 protein.
20
25

Such variations in homology for putative vaccines are well known in the art (See, for example, Hansen et al., "Active and Passive Immunity Against *Borelia* bergdorferi Decorin Binding Protein A (DbpA)," Infection and Immunity, (May) 30 1998, p. 2143 – 2153; Roberts et al., "Heterogeneity Among Genes Including

Decorin Binding Proteins A and B of *Borelia* *bergdorferi* *sensu lato*," Infection and Immunity, (Nov) 1998, p. 5275-5285). Such observations would similarly apply to portions of the proteins disclosed herein.

5 Such fragments or segments find a multitude of uses. For example, such segments of the polypeptides according to the present invention find use as intermediates in the synthesis of higher molecular weight structures also within the present invention.

10 The term "active fragment" or "immunogenic fragment" means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human.

15 As noted, the polypeptides, fragments or other derivatives, or analogs thereof, or cells expressing them, can be used as an immunogen to produce antibodies thereto. These antibodies can be, for example, polyclonal, monoclonal, chimeric, single chain, Fab fragments, or the product of an Fab expression library. Various procedures known in the art may be used for the production of polyclonal 20 antibodies, especially where these are in the form of antisera raised against the polypeptides, or fragments thereof, according to the present invention. Such antisera find use in immunization against pneumococcal infection.

25 Antibodies generated against a polypeptide vaccine corresponding to a sequence of the present invention can be obtained by direct injection of the polypeptide into an animal or by administering the polypeptide to an animal, preferably a nonhuman. The antibody so obtained will then bind the polypeptide itself. In this manner, even a sequence encoding only a fragment of the 30 polypeptide can be used to generate antibodies binding the whole native polypeptide.

For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler and Milstein, 1975, *Nature*, 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 5 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole, et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).

Thus, the present invention also relates to the use of the novel polypeptides disclosed herein, as well as to immunogenic fragments thereof, for the production of lymphocytes, or hybridoma cells, producing monoclonal antibodies against such polypeptides, or immunogenic fragments thereof. The present invention also relates to the hybridoma cells producing such antibodies.

15 Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce single chain antibodies to immunogenic polypeptide products of this invention.

20 The antibodies can be used in methods relating to the localization and activity of the protein sequences of the invention, e.g., for imaging these proteins, measuring levels thereof in appropriate physiological samples and the like, and for other diagnostic applications.

A vaccine in accordance with the present invention may include one or 25 more of the hereinabove described polypeptides or active fragments thereof. When employing more than one polypeptide or active fragment, such as two or more polypeptides and/or active fragments may be used as a physical mixture or as a fusion of two or more polypeptides or active fragments. The fusion fragment or fusion polypeptide may be produced, for example, by recombinant techniques 30 or by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.

In many cases, a variation in the polypeptide or active fragment is a conservative amino acid substitution, although other substitutions are within the scope of the invention.

5

In accordance with the present invention, a polypeptide variant includes variants in which one or more amino acids are substituted and/or deleted and/or inserted.

10

In another aspect, the invention relates to passive immunity vaccines formulated from antibodies against a polypeptide or active fragment of a polypeptide of the present invention. Such passive immunity vaccines can be utilized to prevent and/or treat pneumococcal infections in patients. In this manner, according to a further aspect of the invention, a vaccine can be produced

15

from a synthetic or recombinant polypeptide of the present invention or an antibody against such polypeptide.

20

As already described, another aspect the present invention relates to a method of using one or more antibodies (monoclonal, polyclonal or sera) to the polypeptides of the invention as described above for the prophylaxis and/or treatment of diseases that are caused by pneumococcal bacteria. In particular, the invention relates to a method for the prophylaxis and/or treatment of infectious diseases that are caused by *S. pneumoniae*. In a still further preferred aspect, the invention relates to a method for the prophylaxis and/or treatment of otitis media, nasopharyngeal and bronchial infections, and the like in humans by utilizing a vaccine of the present invention.

25

Generally, vaccines are prepared as injectables, in the form of aqueous solutions or suspensions. Vaccines in an oil base are also well known such as for inhaling. Solid forms which are dissolved or suspended prior to use may also be formulated. Pharmaceutical carriers, diluents and excipients are generally added

30

that are compatible with the active ingredients and acceptable for pharmaceutical use. Examples of such carriers include, but are not limited to, water, saline solutions, dextrose, or glycerol. Combinations of carriers may also be used.

5 Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.

Vaccines are generally formulated for parenteral administration and are
10 injected either subcutaneously or intramuscularly. Such vaccines can also be formulated as suppositories or for oral administration, using methods known in the art, or for administration through nasal or respiratory routes.

The amount of vaccine sufficient to confer immunity to pathogenic bacteria
15 is determined by methods well known to those skilled in the art. This quantity will be determined based upon the characteristics of the vaccine recipient and the level of immunity required. Typically, the amount of vaccine to be administered will be determined based upon the judgment of a skilled physician. Where vaccines are administered by subcutaneous or intramuscular injection, a range of .5 to 500
20 μ g purified protein may be given.

The present invention is also directed to a vaccine in which a polypeptide or active fragment of the present invention is delivered or administered in the form of a polynucleotide encoding the polypeptide or active fragment, whereby the
25 polypeptide or active fragment is produced *in vivo*. The polynucleotide may be included in a suitable expression vector and combined with a pharmaceutically acceptable carrier.

In addition, the polypeptides of the present invention can be used as
30 immunogens to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in other

processes such as affinity chromatography.

In another aspect the present invention provides polynucleotides which encode the hereinabove described polypeptides and active fragments of the invention. The polynucleotide of the present invention may be in the form of RNA or in the form of DNA, which DNA includes cDNA, genomic DNA, and synthetic DNA. The DNA may be double-stranded or single-stranded, and if single stranded may be the coding strand or non-coding (anti-sense) strand.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors comprising a polynucleotide encoding a polypeptide of the invention. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the polynucleotides which encode such polypeptides. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

Vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be mentioned: LTR or SV40 promoter, the E. coli lac or trp, the phage lambda P_L promoter and other 5 promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for amplifying expression.

10 In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

15 The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the proteins.

20 As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of 25 those skilled in the art from the teachings herein.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a 30 sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises

regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example. Bacterial: pQE70, pQE60, pQE-9 (Qiagen, Inc.), pBS, pD10, 5 phagescript, psiX174, pbluescript SK, pBS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia). Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.

10

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and TRP. Eukaryotic 15 promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

15

20

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium 25 phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

30

The constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples including the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable

translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host. Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, *Salmonella typhimurium* and various species within the genera *Pseudomonas*, *Streptomyces*, and *Staphylococcus*, although others may also be employed as a matter of choice, including streptococcal species, especially *S. pneumoniae*.

In a further embodiment, microbial organisms genetically transformed with polynucleotides expressing Sp128 or Sp130, or both, may themselves be used as living vaccine delivery vehicles. Examples include, but are in no way limited to, *Salmonella* species, *Mycobacterium* species, *Streptococcus* species, poxviruses, adenoviruses, and the like. In addition, transgenic edible plants may also be candidates for vaccine delivery.

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and pGEM1 (Promega, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or

chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, a french press, 5 mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art. However, preferred are host cells which secrete the polypeptide of the invention and permit recovery of the polypeptide from the culture media.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

The polypeptides can be recovered and/or purified from recombinant cell cultures by well-known protein recovery and purification methods. Such methodology may include ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. In this respect, chaperones may be used in such a refolding procedure. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The polypeptides that are useful as immunogens in the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated.

- 10 Procedures for the isolation of the individually expressed polypeptides may be isolated by recombinant expression/isolation methods that are well-known in the art. Typical examples for such isolation may utilize an antibody to a conserved area of the protein or to a His tag or cleavable leader or tail that is expressed as part of the protein structure.
- 15 Specific embodiments of the invention will now be further described in more detail in the following non-limiting examples and it will be appreciated that additional and different embodiments of the teachings of the present invention will doubtless suggest themselves to those of skill in the art and such other 20 embodiments are considered to have been inferred from the disclosure herein.

EXAMPLE 1

- 25 Active Protection with Anti-Sp128 and Anti-Sp130

A. Cloning, Expression, and Purification of Sp128 and Sp130.

The genomic DNA used as target for amplification using the polymerase chain reaction was isolated from *Streptococcus pneumoniae* (Norway strain – serotype 4), the same strain used for genomic sequencing. The nucleotide

sequence of the gene fragments encoding Sp128 (SEQ ID NO: 5) and Sp130 (SEQ ID NO: 7) with the corresponding amino acid sequence for polypeptides Sp128 (SEQ ID NO: 6) and Sp130 (SEQ ID NO: 8) are provided in the Sequence Listing.

5

Primers (SEQ ID NOS: 1 – 4) were designed so as to amplify either Sp128 or Sp130 gene fragments and allow their cloning into the *E. coli* expression vector pQE10 with, for example, subsequent expression of a histidine-tagged protein product for purification by Nickel-affinity chromatography.

10

Thus, cloning of the fragments amplified by the primers of SEQ ID NOS: 1 and 2 results in the polypeptide of SEQ ID NO: 6 (denoted Sp128), while cloning of the fragment amplified using the primers disclosed in SEQ ID NOS: 3 and 4 result in the polypeptide of SEQ ID NO: 8 (denoted Sp130).

15

B. Vaccination With Sp128 and Sp130 Results in Protection Against Lethal *S. pneumoniae* Challenge

20

In each of the experiments shown in Figure 1, C3H/HeJ mice (10 per group) were immunized intraperitoneally (i.p.) with either Sp128 or Sp130 protein (15 µg in 50 µl PBS (phosphate buffered saline) emulsified in 50 µl complete Freund's adjuvant (CFA)). A group of 10 mice were sham-immunized with PBS and CFA only.

25

A second immunization of 15 µg protein with incomplete Freund's adjuvant (IFA) was administered 3 weeks later (with the sham-immunized group receiving PBS and IFA).

30

Blood was drawn (retro-orbital bleed) at week 7. Sera from each group were pooled for analysis of anti-Sp128 and anti-Sp130 antibody by ELISA. Mice were

challenged at week 8 by intraperitoneal injection of approximately 400 CFU (colony forming units) of *S. pneumoniae* strain SJ2 (capsular serotype 6B). In preliminary experiments, the median infection dose (LD_{50}) of this strain was determined to be approximately 10 CFU. Mice were monitored for 14 days of survival.

Both experiments shown in Figure 1 used the same preparations of recombinant Sp128 and Sp130.

In the experiment shown in Figure 1A, 7-week serum collected from the 10 mice immunized with either Sp128 or Sp130 each had an endpoint ELISA titer of 1:2,048,000 and 1:1,024,000, respectively. No anti-Sp128 or anti-Sp130 antibody was detected in sera from sham-immunized mice. Ninety percent of the mice immunized with either Sp128 or Sp130 protein survived the challenge (406 CFU of pneumococci) for the extent of the study (14 days). One hundred percent of sham-immunized mice were dead by day 7.

In the experiment shown in Figure 1B, 7-week sera collected from the 10 mice immunized with either Sp128 or Sp130 each had an endpoint ELISA titer of 1:1,024,000 and 1:512,000, respectively. No anti-Sp128 or anti-Sp130 antibody was detected in sera from sham-immunized mice. Ninety and one hundred percent of the mice immunized with either Sp128 or Sp130 protein, respectively, survived the challenge (404 CFU of pneumococci) for the extent of the study (14 days). One hundred percent of sham-immunized mice were dead by day 5.

These data indicate that immunization of mice with either recombinant Sp128 or Sp130 proteins elicit a response capable of protecting against systemic pneumococcal infection and subsequent death. Cross protection is demonstrated by the fact that the recombinant pneumococcal protein was generated based on capsular serotype 4 DNA sequence, while the challenge was with the heterologous strain SJ2 (capsular serotype 6B).

EXAMPLE 2

Passive Protection With Anti-Sp130 Antisera

5 A. Generation of Rabbit Immune Sera

Following collection of pre-immune serum, a New Zealand White rabbit was immunized with 250 µg of Sp130 (SEQ ID NO:8) in complete Freund's adjuvant. The rabbit was given 2 boosts of 125 µg Sp130 in incomplete Freund's adjuvant
10 on days 21 and 52, and bled on days 31 and 62.

B. Passive Protection in Mice

15 BALB/cByJ mice (10 per group) were passively immunized by 2 i.p. injections of 100 µl of rabbit serum. The first injection was administered 24 hours before challenge with 1400 CFU of *S. pneumoniae* strain WU2, and the second injection was given 4 hours after challenge. Figure 2 shows the survival of mice after infection with WU2 (capsular serotype 3) strain. In preliminary experiments,
20 the LD₅₀ of this strain was determined to be approximately 100 CFU.

Figure 2 shows the survival of mice injected with 1400 CFU of strain WU2. As shown therein, 70% of the mice immunized with rabbit immune serum raised against Sp130 protein survived the 10 day observation period. Of the mice
25 immunized with the control serum (collected from a rabbit prior to immunization), 100% died by day 4.

These data suggest that the protection against pneumococcal infection resulting from immunization with Sp130 is antibody-mediated, since the mice
30 were protected by passive transfer of serum from a hyperimmunized rabbit. As seen in the previously described mouse active challenge experiments, serum

directed against recombinant Sp130 protein cloned from a serotype 4 strain was protective against challenge with a heterologous strain, WU2 (capsular serotype 3).

5

EXAMPLE 3

Conservation of Sp128-Sp130 Among Strains of *S. pneumoniae*

10 A. Western Blotting

The pneumococcal strains used in this experiment were obtained from the American Type Culture Collection (Rockville, MD) and include one isolate from each of the serotypes in the currently used multivalent pneumococcal vaccine.

15

For total cell lysates, pneumocci were grown to mid-logarithmic phase (absorbance at 620 nm was 0.4 to 0.6) in 2 ml Todd-Hewitt broth with 5% yeast extract (from Difco, Detroit, MI) at 37°C. Bacteria were harvested by centrifugation and washed twice with water. Pellets (consisting of sedimented 20 cells) were resuspended in 200 µl of lysis buffer (0.01% sodium dodecyl sulfate, 0.15 M sodium citrate, and 0.1% sodium deoxycholate) and incubated at 37°C for 30 min, then diluted in an equal volume of 2X SSC (0.3 M NaCl, 0.03 M sodium citrate). Polypeptides in the lysates were resolved on SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), transferred to 25 nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA) and probed with antibody by conventional Western Blotting procedures. Sera from a New Zealand White rabbit immunized with Sp130 (as per Example 2, supra) was used at a dilution of 1:3000. Bound antibody was detected with peroxidase-conjugated sheep anti-rabbit IgG using a chemiluminescence kit from Amersham 30 Inc. (Cambridge, MA).

The rabbit anti-Sp130 sera revealed 2 major bands with apparent molecular weights of 110 kD and 220 kD in all 23 pneumococcal lysates tested (as shown in Figure 3).

5 These data show that Sp130 is expressed and shares common antigenic epitopes among strains of the 23 pneumococcal capsular serotypes represented in the currently used polysaccharide vaccine.

10

EXAMPLE 4

Immunogenicity of Sp128 and Sp130 in Humans

Sera from patients with culture-proven pneumococcal bacteremia were used
15 in Western blots containing recombinant Sp128 or Sp130 protein. In the experiment shown in Figure 4, sera from 5 patients (indicated by numerals 1 through 5) were diluted 1:3000 and used to probe blots containing Sp128 (SEQ ID NO:6) or Sp130 (SEQ ID NO:8).

20 The lanes labeled "A" (for "acute") were probed with serum collected shortly after diagnosis of pneumococcal infection; lanes denoted "C" (for "convalescent") were probed with serum collected either 1 month later (patients 1, 2, and 3) or 8 days after the first serum collection (patients 4 and 5). For patients 2, 3, and 5, reactivity of the convalescent serum with Sp128 and Sp130
25 was stronger than that of the corresponding acute serum.

Other experiments (not depicted in the figure) showed that convalescent sera from 17 patients with pneumococcal infections were tested individually for reactivity with either Sp128 or Sp130. Thus, 10 and 15 of the 23 sera were found
30 to bind (on a Western Blot) Sp128 and Sp130, respectively.

These experiments indicate that Sp128 and Sp130 (the latter to a greater extent), are recognized by the human immune system and suggest that antibodies able to bind the Sp128-Sp130 protein may be produced during natural *S. pneumoniae* infection in humans. Further, this provides indirect evidence that 5 Sp128 and Sp130 are expressed *in vivo* by *S. pneumoniae* during this phase of infection, and thus may be available as targets for immunoprophylaxis, immunotherapy, or to provide anamnestic immune responses in subjects vaccinated with these proteins. Since the patients were infected with a variety of pneumococcal strains, these data also support the idea that Sp130 is more 10 antigenically conserved than Sp128.